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ABSTRACT
Infections by Aspergillus spp. are most typically associated with invasive pulmonary aspergillosis.
However, an increasing number of reports deal with unusual manifestations of invasive aspergillosis. In
the lung this may take the form of chronic invasive pulmonary aspergillosis, bronchocentric
granulomatosis or tracehobronchitis. A number of extrapulmonary infections have been noted,
sometimes in immunocompetent individuals. Examples include vertebral osteomyelitis, primary
cutaneous aspergillosis (such as in premature neonates), prosthetic vascular graft infection and
infective endocarditis. Early recognition of these entities, prompt initiation of new, highly active
antifungal therapies and adjunctive surgical management may improve the prognosis of these
conditions.
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INTRODUCTION
Invasive aspergillosis has classically been associ-
ated with pulmonary infection. Invasive pulmon-
ary aspergillosis is the most common
manifestation of serious aspergillus infection in
all hosts. Other pulmonary manifestations include
aspergilloma or allergic bronchopulmonary
aspergillosis. This paper will not discuss these
conditions but instead will focus on a number of
extrapulmonary manifestations and some rare
pulmonary manifestations of invasive aspergil-
losis (Table 1).
ASPERGILLUS VERTEBRAL
OSTEOMYELITIS
Aspergillus spp. may occasionally infect bone
[1–48]. The most commonly reported site of
infection has been the spine. Of reported cases,
the lumbar vertebrae were infected in 53% of
cases, the thoracic vertebrae in 46% of cases and
the cervical vertebrae in just 2% of cases [20]. A
surprisingly high proportion of patients (34%)
have no underlying immunocompromise [20].
Some of these patients had a history of previous
laminectomy and discectomy. Those with under-
lying immunocompromise had been receiving
corticosteroids, chemotherapy, or transplant im-
munosuppression or had neutropenia or chronic
granulomatous disease. Presumably most cases
Table 1. Classical and emerging clinical presentations of
invasive aspergillosis
Classical presentations
Acute invasive pulmonary aspergillosis
Aspergillus invasive sinusitis
Disseminated infection, including cerebral aspergillosis
Emerging extrapulmonary infections
Primary cutaneous aspergillosis
Aspergillus osteomyelitis
Vascular graft infection
Emerging pulmonary infections
Tracheobronchitis
Chronic invasive pulmonary aspergillosis
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arise from haematogenous spread from a distant
site, but a few cases have occurred from direct
extension from a pulmonary or aortic focus. There
is a bimodal age distribution amongst reported
cases—children with chronic granulomatous dis-
ease and then older adults with other underlying
disorders.
Back pain is an almost universal initial
symptom of vertebral osteomyelitis caused by
Aspergillus spp. Unfortunately some patients
have presented with paraparesis [20]. The neu-
rological prognosis for patients who present
with paraparesis is extremely poor. Surprisingly
few patients have elevated peripheral white
blood cell count (just 28% of those reported
have had a white blood cell count greater than
11 000 ⁄mm3) [20]. However, the majority have
an elevated erythrocyte sedimentation rate
(although occasional patients have been noted
with an erythrocyte sedimentation rate less than
40 mm ⁄h).
The clinical approach to aspergillus vertebral
osteomyelitis depends on age, underlying med-
ical conditions and evidence of structural insta-
bility or neural compression. When spinal
instability or symptoms of spinal cord or radicu-
lar compression are present, surgical decompres-
sion is indicated [20]. The type and extent of
surgery should be individualised; some patients
may merely require percutaneous needle aspir-
ation while others will require laminectomy with
abscess drainage or debridement, with or without
autologous bone grafting. Systemic antifungal
therapy should be administered in all cases. The
mortality rate from reported cases has been 26.8%
[20].
NEONATAL PRIMARY CUTANEOUS
ASPERGILLOSIS
A number of reports have emerged, predomin-
antly in the last 10 years, of cutaneous aspergillus
infection in neonates [49–61]. At least 80% of
these infections have been in premature infants,
with gestational ages from 24 to 32 weeks at the
time of birth, and birthweights of 440–1500 g. The
infection occurs in the ﬁrst month of life.
Premature infants are known to have func-
tional impairment of neutrophils and monocytes,
despite normal number of these cells [62]. Addi-
tionally, many premature ventilated neonates are
receiving systemic corticosteroids. At least eight
of the 18 cases reported thus far have received
systemic corticosteroids. Finally, the skin barrier
of premature infants is inadequate because of
their immaturity, and is subject to trauma from
intravenous catheter insertion, tape removal, arm
boards and pulse oximeters.
The skin lesions of neonatal premature cutane-
ous aspergillosis typically begin as an erythema-
tous patch or plaque that develops pustules and
eventually ulcerates to form a necrotic eschar [49].
The initial erythematous plaque may be mistaken
for an early bedsore, or even an incarcerated
inguinal hernia [49]. By deﬁnition, primary
cutaneous aspergillosis is conﬁned to the skin,
without infection in other organs. However,
without prompt diagnosis and treatment, sys-
temic infection may follow. Most cases have been
as a result of A. fumigatus or A. ﬂavus infection.
CUTANEOUS INFECTION DUE TO
ASPERGILLUS USTUS
A. ustus is a rarely described Aspergillus species.
However, a number of recent reports have
documented human infection with this fungus
[63–70]. On malt extract agar, A. ustus colonies
are dense, cottony, brownish grey, white at the
periphery, with a yellow diffusing pigment.
Colonial features on potato dextrose agar are
similar but a typical brownish exudate may be
produced. The microscopic appearance is of
smooth, brown, thick-walled conidiophores up
to 250 lm long by 5 lm wide, with biseriate
conidial heads composed of metulae up to 6 lm
long by 4 lm wide, and phialides up to 6 lm
long by 3.5 lm wide. The conidia are globose,
4–5 lm in diameter, and brown with very rough
walls. Irregularly elongated, slightly curved or
twisted Hu¨lle cells are often profusely produced
in all media.
Previously reported infections with A. ustus
have been almost exclusively of the lungs or skin.
Cutaneous infections have been in patients im-
munosuppressed by use of systemic corticoster-
oids or by transplant immunosuppression
[63,64,68]. In one reported case, the infection
commenced in an area of the skin traumatized
after a fall [64]. Interestingly, terbinaﬁne has been
the most active agent in vitro against these strains
[64,65]. In one of only two cases which have been
successfully treated, the patient received therapy
with topical terbinaﬁne [68].
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PROSTHETIC VASCULAR GRAFT
INFECTION BY ASPERGILLUS IN
IMMUNOCOMPETENT PATIENTS
Bacterial infection of vascular prosthetic grafts is a
serious event but occurs in less than 3% of
patients with grafts in place. Fungal infections of
vascular grafts are even less frequent; fewer than
20 cases of prosthetic vascular graft infection by
Aspergillus spp. have thus far been reported
[10–12,71–80]. Interestingly, all of the patients
have been immunocompetent, raising suspicions
that the grafts were contaminated at the time of
surgery. Presumably this is by contamination of
the graft in the operating room with airborne
fungal spores.
The majority of infections have been either at
the thoracic or abdominal aorta. The median time
from placement of the graft to diagnosis has been
8 months. Not all patients have presented with
fever but most patients had elevated white blood
cell counts and erythrocyte sedimentation rates.
Four reported cases have had coexisting vertebral
osteomyelitis.
Medical therapy, alone, is unlikely to cure the
infection. Resection of the infected graft and
placement of an extra-anatomic bypass through
a clean ﬁeld appears to be the key to a successful
outcome [72].
ASPERGILLUS ENDOCARDITIS IN
SOLID-ORGAN TRANSPLANT
RECIPIENTS
Fungi are an important cause of endocarditis in
solid-organ transplant recipients [81]. Fewer than
20 cases have been reported in published litera-
ture as being the result of Aspergillus spp. infec-
tion, but a number of common characteristics
have emerged [81–89]. Liver, lung, heart and
kidney transplant recipients with aspergillus
endocarditis have been described.
There appears to be a bimodal distribution in
terms of time from transplantation to develop-
ment of endocarditis. One subgroup of patients
comprises those with an extremely stormy early
post-transplant course with poor function of the
transplant organ and renal failure. These patients
develop disseminated aspergillosis, including
endocarditis, and die within 30 days of trans-
plantation. Endocarditis is not suspected prior to
death but is discovered at autopsy. Characteristi-
cally, these patients have infection of the mural
endocardium rather than of the valvular endo-
cardium.
A second, and somewhat smaller, subgroup
comprises patients who manage to leave hospital
but who develop aspergillus endocarditis in the
second year after transplantation. These patients
may have received augmented immunosuppres-
sion for treatment of rejection or may have a
history of recent cytomegalovirus infection (which
also contributes to immunosuppression) [86,88].
At least two such patients have presented with
peripheral embolic phenomena [87,88]. These
patients also presented evidence of arterial occlu-
sion, one presenting with a painful, pulseless arm,
the other with acute renal failure associated with
thrombosis of the renal arteries. In both cases a
surgically excised thrombus grew A. fumigatus.
Despite treatment, all of these patients have died.
It should be noted that, unlike infective endo-
carditis caused by other organisms, aspergillus
endocarditis is exceedingly rarely associated with
positive blood cultures. Transthoracic echocardi-
ography may not detect some cases of aspergillus
endocarditis visualised by transoesophageal echo-
cardiography [88].
Treatment of previously documented cases of
aspergillus endocarditis suspected during life has
comprised conventional amphotericin or a lipid
preparation of amphotericin. Given recent data
showing the superiority of voriconazole over
amphotericin for invasive aspergillosis [90], vor-
iconazole may be considered the drug of choice
for aspergillus endocarditis. However, there are a
number of caveats to this statement. Although
immunosuppression should be reduced as much
as possible during treatment of invasive aspergil-
losis, voriconazole may signiﬁcantly inhibit the
metabolism of cyclosporine or tacrolimus. Addi-
tionally, many patients who develop invasive
aspergillosis post-transplant will have renal fail-
ure, yet intravenous voriconazole is not recom-
mended when creatinine clearance falls below
50 mL ⁄min because accumulation of the intra-
venous vehicle, sulphobutyl ether b-cyclodextrin
sodium, occurs in renal failure. At the present
time, the role of a combination of voriconazole
with amphotericin or caspofungin is uncertain,
but animal data [91] would suggest that this
combination may provide additional beneﬁts. It is
also recommended that patients with aspergillus
endocarditis be considered potential candidates
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for valve replacement surgery. Unfortunately
patients with disseminated aspergillosis rarely
have the general physiology capable of with-
standing such an operation.
It should be noted that a number of less
common molds have been observed to cause
endocarditis in transplant recipients. These may
initially be mistaken for aspergillus infection.
Examples include Phaeoacremonium parasiticum in
a liver transplant recipient [92], Fusarium solani in
a lung transplant recipient [93], Cunninghamella
bertholletiae in a kidney transplant recipient [94]
and Pseudallescheria boydii in a liver transplant
recipient [95]. Like aspergillus endocarditis, the
infection is disseminated and almost universally
fatal. Each of these cases has occurred in the ﬁrst
4 months post-transplant and has involved right-
sided valves.
UNUSUAL RESPIRATORY
MANIFESTATIONS OF INFECTION
WITH ASPERGILLUS SPP .
In settings other than transplantation or neutro-
penia, patients with invasive pulmonary asper-
gillosis may present with symptoms progressing
over several weeks to months [96–100]. This
chronic form of invasive pulmonary aspergillosis
is considerably less common than the acute
invasive form. Patients may lack immunocom-
promise or may have received corticosteroids for
chronic pulmonary diseases such as sarcoidosis,
may be alcoholic or have diabetes mellitus,
chronic granulomatous disease, or human immu-
nodeﬁciency virus (HIV) infection. The usual
symptoms are chronic productive cough, low-
grade fever, occasional haemoptysis, malaise and
weight loss. Radiologically, cavitation of an area
of consolidated lung is usual. The ﬁnding of
Aspergillus in sputum is suggestive, but smokers
may have colonisation in the absence of invasive
disease. Diagnosis therefore usually requires
biopsy evidence of invasive aspergillus hyphae
in lung tissue. However, hyphae are often scant.
Granulomata are typical; sometimes the process is
described histologically as an angioinvasive nec-
rotizing granulomatous pneumonia.
One histologic appearance of chronic pulmon-
ary aspergillosis is bronchocentric granulomatosis
[101–103]. About 50% of patients have asthma.
Hence, bronchocentric granulomatosis is regard-
ed by some as more akin to a localised allergic
bronchopulmonary aspergillosis than to a true
invasive process. Patients usually have chronic
symptoms such as cough, low-grade fever, mal-
aise, dull chest pain and haemoptysis. Radiolo-
gically, a focal upper lobe lesion is usually seen.
Aspergillus tracheobronchitis is seen character-
istically in lung transplant recipients, although it
has also been observed rather commonly in HIV-
infected and immunocompetent patients [104–
107]. Rare cases have been reported in other
groups, such as bone marrow transplant recipi-
ents. In lung transplant recipients the disease
usually occurs in the ﬁrst month post-transplant.
Tracheobronchitis is observed on routine bronch-
oscopy, centered around the suture line. Patients
are generally asymptomatic or have symptoms
attributable to the transplant, with chest radio-
graphs unchanged from baseline. However, as the
disease progresses, symptoms become more pro-
nounced with a monophonic wheeze becoming
particularly prominent.
Bronchoscopically, the appearance is of severe
tracheobronchitis progressing to multiple ulcers
at the site of anastomosis. Sequelae include acute
invasive pulmonary aspergillosis, severe bron-
chial stenosis, anastomotic dehiscence and bron-
chial necrosis with bronchoarterial ﬁstula
formation. Some patients develop extensive pseu-
domembranes, which can completely occlude the
lumen of large airways. Such patients are ex-
tremely difﬁcult to ventilate, and may die of
respiratory insufﬁciency.
Bronchial stump aspergillosis is a rare and
unusal sequel of lung resection, ﬁrst described in
Japan [108,109]. Typically, 6–12 months after lung
resection (during which silk sutures were used),
the patient develops productive cough and haem-
optysis. The sputum may be foul smelling
and contain fungal material or silk-suture mater-
ial. The cause is secondary colonisation of the
suture material which is protruding into the
bronchial lumen. Local inﬂammation and then
necrosis of the bronchial mucosa result. Chest
radiography is usually unchanged compared to
baseline.
CONCLUSIONS
Invasive aspergillosis has a myriad of clinical
presentations. It has been known for many years
that in disseminated aspergillosis the fungus can
be grown from a huge variety of organs. How-
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ever, a current clinical challenge is the early
detection of invasive aspergillosis isolated to
unusual sites, sometimes even in immunocompe-
tent individuals. The combination of early diag-
nosis, appropriate treatment with new antifungal
options such as voriconazole, and careful consid-
eration of adjunctive surgical therapy should
improve the outcome of such patients.
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